| 2025-12-15 |
详情>>
股本变动：
变动后总股本19299.65万股
变动原因 ▼▲
- 原因：
- Common Stock offered 5,725,190 shares by the company
|
| 2025-11-16 |
详情>>
内部人交易：
Parikh Shamik J等共交易2笔
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.11美元,归母净利润-1602.9万美元,同比去年增长87.45%
|
| 2025-11-12 |
财报披露：
美东时间 2025-11-12 盘前发布财报
|
| 2025-08-11 |
详情>>
业绩披露：
2025年中报每股收益0.01美元,归母净利润148.10万美元,同比去年增长101.67%
|
| 2025-05-13 |
详情>>
业绩披露：
2025年一季报每股收益0.28美元,归母净利润3913.90万美元,同比去年增长222.71%
|
| 2025-04-29 |
股东大会：
将于2025-06-10召开股东大会
会议内容 ▼▲
- 1.To elect Brady W. Dougan, C. Bruce Green, Diane Seimetz and Max Wallace to serve as Class I directors until the 2028 annual meeting of stockholders;
2.To ratify the selection of PricewaterhouseCoopers LLP by the Board of Directors as the independent registered public accounting firm of the Company for the year ending December 31, 2025;
3.To approve an amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to increase the total number of authorized shares of common stock from 250,000,000 shares to 350,000,000 shares;
4.To transact any other business properly brought before the Annual Meeting or any adjournments or postponements thereof.
|
| 2025-03-31 |
详情>>
业绩披露：
2024年年报每股收益-1.26美元,归母净利润-1.49亿美元,同比去年增长-34.24%
|
| 2024-11-08 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.1美元,归母净利润-1.28亿美元,同比去年增长-49.13%
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-0.78美元,归母净利润-8855.9万美元,同比去年增长-48.4%
|
| 2024-05-13 |
详情>>
业绩披露：
2024年一季报每股收益-0.29美元,归母净利润-3189.6万美元,同比去年增长13.72%
|
| 2024-04-29 |
股东大会：
将于2024-06-11召开股东大会
会议内容 ▼▲
- 1.To elect John P. Bamforth, Emery N. Brown, Michael T. Constantino, Keith Anthony Jones, Laura E. Niklason and Susan Windham-Bannister to serve as Class III directors until the 2027 annual meeting of stockholders;
2.To ratify the selection of PricewaterhouseCoopers LLP by the Board of Directors as the independent registered public accounting firm of the Company for the year ending December 31, 2024;
3.To transact any other business properly brought before the Annual Meeting or any adjournments or postponements thereof.
|
| 2024-03-28 |
详情>>
业绩披露：
2023年年报每股收益-1.07美元,归母净利润-1.11亿美元,同比去年增长-825.83%
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.83美元,归母净利润-8567万美元,同比去年增长-939.05%
|
| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-0.58美元,归母净利润-5967.5万美元,同比去年增长-450.29%
|
| 2023-04-28 |
股东大会：
将于2023-06-07召开股东大会
会议内容 ▼▲
- 1.To elect Gordon M. Binder, Todd M. Pope, Kathleen Sebelius and Rajiv Shukla to serve as Class II directors until the 2026 annual meeting of stockholders;
2.To ratify the selection of PricewaterhouseCoopers LLP by the Board of Directors as the independent registered public accounting firm of the Company for the year ending December 31, 2023;
3.To transact any other business properly brought before the Annual Meeting or any adjournments or postponements thereof.
|
| 2022-04-29 |
股东大会：
将于2022-06-09召开股东大会
会议内容 ▼▲
- 1.To elect Brady Dougan, Diane Seimetz and Max Wallace to serve as Class I directors until the 2025 annual meeting of stockholders;
2.To ratify the selection of PricewaterhouseCoopers LLP by the Board of Directors as the independent registered public accounting firm of the Company for the year ending December 31, 2022;
3.To transact any other business properly brought before the Annual Meeting or any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-27 |
复牌提示：
2021-08-27 09:57:07 停牌，复牌日期 2021-08-27 10:07:07
|
| 2021-08-04 |
股东大会：
将于2021-08-24召开股东大会
会议内容 ▼▲
- 1.to (a) adopt and approve the Business Combination Agreement, dated as of February 17, 2021 (the “Business Combination Agreement”), among AHAC, Hunter Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of AHAC (“Merger Sub”), and Humacyte, Inc., a Delaware corporation (“Humacyte”), pursuant to which Merger Sub will merge with and into Humacyte, with Humacyte surviving the merger as a wholly-owned subsidiary of AHAC (the “Combined Company”) and (b) approve such merger and the other transactions contemplated by the Business Combination Agreement (the “Business Combination”). Subject to the terms and conditions set forth in the Business Combination Agreement, at the effective time of the Business Combination (the “Effective Time”):(i)each outstanding share of Humacyte common stock will be cancelled and converted into the right to receive a number of shares of common stock of New Humacyte (the “New Humacyte common stock”) equal to the Exchange Ratio (as defined in the accompanying proxy statement/prospectus);(ii)each outstanding share of Humacyte preferred stock will be cancelled and converted into the right to receive a number of shares of New Humacyte common stock equal to (A) the aggregate number of shares of Humacyte common stock that would be issued upon conversion of the shares of Humacyte preferred stock based on the applicable conversion ratio immediately prior to the Effective Time, multiplied by (B) the Exchange Ratio (as defined in the Business Combination Agreement);(iii)each outstanding Humacyte option or warrant will be converted into an option or warrant, as applicable, to purchase a number of shares of New Humacyte common stock equal to (A) the number of shares of Humacyte common stock subject to such option or warrant multiplied by (B) the Exchange Ratio at an exercise price per share equal to the current exercise price per share for such option or warrant divided by the Exchange Ratio; in each case, rounded down to the nearest whole share;(iv)holders of shares of Humacyte common stock and Humacyte preferred stock also will be eligible to receive up to an aggregate of 15,000,000 shares of New Humacyte common stock based on the share price performance of the New Humacyte common stock.
2.to approve, assuming the Business Combination Proposal is approved and adopted, a proposed second amended and restated certificate of incorporation (the “Proposed Charter,” a copy of which is attached to the accompanying proxy statement/prospectus as Annex C), which will amend and restate AHAC’s current Amended and Restated Certificate of Incorporation (the “Current Charter”), and which Proposed Charter will be in effect upon the closing (the “Closing”) of the Business Combination (the “Charter Amendment Proposal”);
3.to approve, on a non-binding advisory basis, the following material differences between the Proposed Charter and the Current Charter, which are being presented pursuant to guidance of the Securities and Exchange Commission as seven separate sub-proposals (the “Advisory Charter Amendment Proposals”):(a)Advisory Charter Proposal A — to change the corporate name of the Combined Company to “Humacyte, Inc.”; (b)Advisory Charter Proposal B — to increase the authorized shares of common stock of AHAC to 250,000,000 shares;(c)Advisory Charter Proposal C — to increase the authorized shares of “blank check” preferred stock that the Combined Company’s board of directors could issue to 20,000,000 shares;(d)Advisory Charter Proposal D — to provide that the removal of any director be only for cause and by the affirmative vote of at least 66% of the Combined Company’s then-outstanding shares of capital stock entitled to vote generally in the election of directors;(e)Advisory Charter Proposal E — to provide that certain amendments to provisions of the Proposed Charter will require the approval of at least 66% of the Combined Company’s then-outstanding shares of capital stock entitled to vote on such amendment;(f)Advisory Charter Proposal F—to make the Combined Company’s corporate existence perpetual instead of requiring AHAC to be dissolved and liquidated 24 months following the closing of AHAC’s initial public offering (the “Initial Public Offering”), and to remove from the Proposed Charter the various provisions applicable only to special purpose acquisition companies;(g)Advisory Charter Proposal G—to remove the provision that allows stockholders to act by written consent as opposed to holding a stockholders meeting;
4.to approve, assuming the Business Combination Proposal is approved and adopted, for purposes of complying with the applicable provisions of Nasdaq Stock Exchange Listing Rule 5635 (the “Nasdaq Listing Rule”), (a) the issuance of up to 95,000,000 shares of New Humacyte common stock in connection with the Business Combination, which amount will be determined as described in more detail in the accompanying proxy statement/prospectus, and (b) the issuance of an aggregate of 17,500,000 shares of AHAC Class A Common Stock in a private placement (the “PIPE Investment”) concurrent with the Business Combination (the “Nasdaq Stock Issuance Proposal”);
5.to approve, assuming the Business Combination Proposal is approved and adopted, the appointment of eleven directors who, upon consummation of the Business Combination, will become directors of the Combined Company (the “Director Election Proposal”);
6.to approve, assuming the Business Combination Proposal is approved and adopted, the Humacyte, Inc. 2021 Long-Term Incentive Plan, a copy of which is attached to the accompanying proxy statement/prospectus as Annex D, which will become effective as of and contingent on the consummation of the Business Combination (the “Incentive Plan Proposal”);
7.to approve, assuming the Business Combination Proposal is approved and adopted, the Humacyte, Inc. 2021 Employee Stock Purchase Plan, a copy of which is attached to the accompanying proxy statement/prospectus as Annex E, which will become effective as of and contingent on the consummation of the Business Combination (the “ESPP Proposal”);
8.to approve a proposal to adjourn the Special Meeting to a later date or dates if it is determined that more time is necessary or appropriate, in the judgment of the board of directors of AHAC or the officer presiding over the Special Meeting, for AHAC to consummate the Business Combination (the “Adjournment Proposal”).
|